NEULANDLABNeuland Laboratories Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on NEULANDLAB — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 136.4% YoY
- • Profit growth: 664.4% YoY
- • ROE: 19.4%
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • Trend strength (ADX): 49
Bull case
- • Revenue growth: 136.4% YoY
- • Profit growth: 664.4% YoY
- • ROE: 19.4%
- • Price vs SMA200: above
Bear case
- • Valuation vs sector: P/E 67.1 vs sector 35.5
- • Dividend yield: 0.17%
- • RSI: 24
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Valuation vs sector: P/E 67.1 vs sector 35.5
- • Dividend yield: 0.17%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹714.42). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.